SecBot SecBot
SECBOTREPLAY Home › Report › INM

INM · InMed Pharmaceuticals has filed an S-3 shelf registration statement…

InMed Pharmaceuticals Inc. · S-3 filed Mar 20, 2026 at 17:00 ET

At the news

BEARISHIMPACT 7/10

S-3 filed Mar 20, 2026 at 17:00 ET

InMed Pharmaceuticals has filed an S-3 shelf registration statement allowing it to raise up to $50 million through future offerings of common shares, preferred shares, warrants, subscription rights, or units. This signals a potential capital raise, which could lead to significant shareholder dilution given the company's current $2 million market cap. The filing comes amid ongoing operating losses and substantial doubt about the company's ability to continue as a going concern, particularly due to adverse U.S. legislation impacting its BayMedica commercial business.

  • InMed filed an S-3 shelf registration allowing for up to $50 million in future securities offerings.
  • The company's market cap is only $2 million, meaning the offering could result in massive dilution of up to 2,500%.
  • InMed has recurring operating losses and an accumulated deficit, with auditors noting substantial doubt about its ability to continue as a going concern.
  • The company's BayMedica commercial business faces material adverse impact from recent U.S. legislation affecting its cannabinoid inventory.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access